DRI-C21045
DRI-C21045 (compound 10) is a potent and selective inhibitor of the CD40-CD40L costimulatory protein-protein interaction (PPI) with an IC50 of 0.17 μM. DRI-C21045 shows concentration-dependent inhibition of the activation of NF-κB and B cell proliferation all induced by CD40L with IC50s of 17.1 μM and 4.5 μM, respectively[1].
Product Specifications
CAS Number
2101765-81-3
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
TNF Receptor
Type
Reference compound
Related Pathways
Apoptosis
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/dri-c21045.html
Purity
98.11
Solubility
DMSO : 2 mg/mL (ultrasonic)
Smiles
O=S(C1=CC=CC2=CC=CC(NC(C3=CC=C(C4=CC=C(NC(C5=CC=C(C(OC)=O)C=C5)=O)C=C4)C=C3)=O)=C21)(O)=O
Molecular Formula
C32H24N2O7S
Molecular Weight
580.61
Precautions
H302, H315, H319
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
P2RX7 (P2X Purinoceptor 7, P2X7, ATP Receptor, P2Z Receptor, Purinergic Receptor, MGC20089) (MaxLight 405)